mark year oper manag host analyst day clinic
test laboratori pittsburgh yesterday perkin leadership prenat newborn
screen appar compar lab offer biochem screen
five year ago today perkin built site offer complementari servic like
non-invas prenat test nipt genet test util novaseq food
tolerance/allergi test euroimmun equip key takeaway
revenu growth gain visibl multipl expans may occur meet
exce organ growth estim
steel citi heart reproduct franchis
seven lab around globe pittsburgh atlanta china india sweden
malaysia pittsburgh lab repres global hq clinic laboratori
servic busi us pittsburgh lab servic state repres
newborn screen us outsid core biochem screen
capabl tour showcas valu proposit vanadi workflow
perkin expand genom capabl expans autoimmune/allergi
test capabl euroimmun site
vanadi showcas highlight valu proposit per manag
mn pregnanc annual mn screen use biochem
method mn mn util base non-invas prenat
method nipt vanadi introduc simpler workflow lower test cost
compar accuraci base method manag key focu
convert legaci biochem base mn nipt method
vanadi offer tour provid opportun take deeper look
vanadi workflow product workflow includ vanadi extract
autom sampl prep machin extract dna ml whole blood
barcod sampl vanadi use rolling-circle-repl amplifi
form dna ball vanadi view count fluorescent-tag dna
softwar life-cycle report analysi walkaway autom
key sell point total hands-on-tim minut versu hour
addit oper vanadi requir level skill
expertis infrastructur requir compar test method
biochem custom lack capabl confirm test
view vanadi competit offer nipt manag note
expect placement year-end sampl midpoint throughput
full menu genom capabl top biochem test perkin
also offer wide menu genet test servic single/multipl gene
panel whole-genom sequenc util perkin sampl prep autom
equip ilmn-neutr novaseq perkin also offer genet
counsel servic enabl healthcar provid famili alik
understand ramif result expans outsourc gene
sequenc build upon perkin core capabl biochem screen
one-stop-shop test enabl full rang care singl
model flow-through maintain current estim howev
tweak organ growth slightli higher base continu euroimmun
strength introduct uptak vanadi continu sequenc growth
still remain skeptic da growth reacceler given
trend key macro indic da increas exposur industri end
market rel peer manag guid bp opm expans
appear achiev given recent execut leverag
increas focu lean oper coupl increment contribut
euroimmun sequenc vanadi therefor increas ep
estim respect
fair valu maintain neutral rate fv fv
reach appli multipl consolid ep
subtract net debt fv also reach appli
multipl ebitda subtract net debt compar
peer trade ep ebitda estim
million except per share data
euroimmun inc dx
amort intang
annual revenu break-out margin
revenu
revenu
